CJC-1295 (No DAC) + Ipamorelin certificate of analysis: lot APL-CJCIP10-2606-01
- Compound
- CJC-1295 (No DAC) + Ipamorelin
- Lot
- APL-CJCIP10-2606-01
- Laboratory
- Supplier lab
- Test
- purity · HPLC
- Result
- 99.33%
- Tested
- 17 June 2026
- Covers stock
- Not current stock
CJC-1295 (No DAC) + Ipamorelin 10 mg from batch APL-CJCIP10-2606-01 was analysed on 17 June 2026 and measured 99.33% combined purity across Ipamorelin and CJC-1295 (No DAC) by HPLC / Mass Spectrometry, passing all 5 release tests.
Combined purity
99.33%
Components
Ipamorelin, CJC-1295 (No DAC)
Result
All 5 tests passed
Tested
17 June 2026
Method
HPLC / Mass Spectrometry
Net content
10.00 mg
Independent verification
CJC-1295 (No DAC) + Ipamorelin 10 mg is independently verified by Ozcanium Analytics, an independent Australian laboratory, at 99.16% purity by UPLC-MS/MS, analysed 27 August 2026 on lot APL-CJCIP10-2608-01, net content Ipamorelin 5.10 mg, CJC-1295 (No DAC) 5.29 mg, verification code OZ-HPLCMS-JKJ2; bacterial endotoxin below 15.0 EU per vial by kinetic chromogenic LAL, analysed 28 August 2026, verification code OZ-ENDOTX-TPA1.
Issued by Ozcanium Analytics . Covers every vial size of this compound; each report opens as the laboratory issued it.
- Third-Party Purity COA (PDF, opens in a new tab) 99.16% purity by UPLC-MS/MS · net content Ipamorelin 5.10 mg, CJC-1295 (No DAC) 5.29 mg Analysed 27 August 2026 Verification code OZ-HPLCMS-JKJ2
- Third-Party Endotoxin Test (PDF, opens in a new tab) Bacterial endotoxin below 15.0 EU per vial by kinetic chromogenic LAL Analysed 28 August 2026 Verification code OZ-ENDOTX-TPA1
Enter a code in the Ozcanium Analytics verification portal (opens in a new tab) to confirm the report against their own records.
The certificate as issued is reproduced below — pinch to zoom on a phone, or use Print / Save as PDF for a full-size copy.
Compound Mix
CJC-1295 (No DAC) + Ipamorelin
Lot Number
APL-CJCIP10-2606-01
Analysis Date
17 June 2026
Method
HPLC / Mass Spectrometry
Purity
99.33%
Net Content
10.00 mg
- Ipamorelin 5.01 mg
- CJC-1295 (No DAC) 4.99 mg
Form
Lyophilised Powder
Manufactured
June 2026
Issued
18 June 2026
Document ID
APL-COA-CJCIP10-2606-01
Verification Code
Batch traceable
High Performance Liquid Chromatography (HPLC-UV) Chromatogram
Components resolved at 3.56 min (Ipamorelin, 39.87%), 4.06 min (CJC-1295 (No DAC), 59.46%); combined peptide area 99.33%. No single impurity peak exceeds 0.26%.
Peak List
| # | Time (min) | Area | % Area | Assignment |
|---|---|---|---|---|
| 1 | 3.565 | 2,932,500 | 39.870 | Ipamorelin |
| 2 | 3.621 | 16,431 | 0.220 | — |
| 3 | 4.064 | 4,373,191 | 59.460 | CJC-1295 (No DAC) |
| 4 | 4.277 | 18,901 | 0.260 | — |
| 5 | 4.628 | 8,367 | 0.110 | — |
| 6 | 5.837 | 5,979 | 0.080 | — |
Analytical Results
| Test | Specification | Result | Status |
|---|---|---|---|
| Appearance | White/Off-White Lyophilised Powder | Conforms | PASS |
| Identity (MS) | All components confirmed | Confirmed | PASS |
| Purity (HPLC) | ≥98.0% combined | 99.33% | PASS |
| Total Peptide Content | 95–105% | 99.1% | PASS |
| Endotoxins | <0.5 EU/mg | <0.15 EU/mg | PASS |
Ipamorelin
PubChem CID: 9831659 · CAS Number: 170851-70-4
Formula: C38H49N9O5 · MW: 711.85 g/mol · In this vial: 5.01 mg
Liquid Chromatography Mass Spectrometry (LC-MS) Identity Analysis
Identity confirmation with SIM
| Monitored (m/z) | Detected (m/z) | Relative Intensity |
|---|---|---|
| 357 | 356.91 | 3 |
| 713 | 712.84 | 2.16 |
Detection assignment: Ipamorelin
Collected Mass Spectrum
Intensity ×10 7
CJC-1295 (No DAC)
PubChem CID: 91971820 · CAS Number: 446262-90-4
Formula: C152H252N44O42 · MW: 3367 g/mol · In this vial: 4.99 mg
Liquid Chromatography Mass Spectrometry (LC-MS) Identity Analysis
Identity confirmation with SIM
| Monitored (m/z) | Detected (m/z) | Relative Intensity |
|---|---|---|
| 674 | 674.4 | 1.04 |
| 843 | 842.79 | 1.44 |
| 1123 | 1123.34 | 1.62 |
Detection assignment: CJC-1295 (No DAC)
Collected Mass Spectrum
Intensity ×10 7
Verification Protocol
- Identity confirmed separately for each component by mass spectrometry against its own expected ion channels.
- Purity measured by HPLC as the combined area of every assigned component peak against all integrated impurity peaks.
- Batch traceability: this document reports the lot number printed on the vial.
- Analysis performed in-house by Australian Peptide Labs.
Supplied for laboratory research use only. Not a therapeutic good; not for human or veterinary use.
View CJC-1295 (No DAC) + Ipamorelin in the catalogue · How to read this certificate
What this report shows
An HPLC purity result is the share of the detected signal that belongs to the main peptide peak. It does not confirm identity (that is mass spectrometry) and it is not net peptide content, which also counts water, counter-ions and salts in the vial.